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Cannabinoids are involved in the regulation of neural stem cell biology and their receptors are 
expressed in the neurogenic niches of adult rodents. In the spinal cord of rats and mice, neural stem 
cells can be found in the ependymal region, surrounding the central canal, but there is evidence 
that this region is largely different in adult humans: lacks a patent canal and presents perivascular 
pseudorosettes, typically found in low grade ependymomas. Using Laser Capture Microdissection, 
Taqman gene expression assays and immunohistochemistry, we have studied the expression of 
endocannabinoid system components (receptors and enzymes) at the human spinal cord ependymal 
region. We observe that ependymal region is enriched in CB1 cannabinoid receptor, due to high CB1 
expression in GFAP+ astrocytic domains. However, in human spinal cord levels that retain central 
canal patency we found ependymal cells with high CB1 expression, equivalent to the CB1HIGH cell 
subpopulation described in rodents. Our results support the existence of ependymal CB1HIGH cells 
across species, and may encourage further studies on this subpopulation, although only in cases 
when central canal is patent. In the adult human ependyma, which usually shows central canal 
absence, CB1 may play a different role by modulating astrocyte functions.
The Endocannabinoid System (ECBS) is formed by lipid ligands (endocannabinoids), the enzymatic 
machinery for their synthesis and degradation and their specific G-protein coupled CB1 and CB2 recep-
tors. The most important endocannabinoids are 2-arachydonoylglycerol (2-AG) and anandamide (AEA)1. 
These compounds are involved in the control of neural stem cell biology2, and many of their effects are 
mediated by the cannabinoid receptor CB1. CB1 receptor is expressed in all neurogenic niches in rodents, 
including the ependymal region of the spinal cord (reviewed in3). In this region, that holds neural stem 
cell potential4,5, a subpopulation of cells expresses high levels of CB1 receptor (CB1HIGH cells), and prolif-
erate after lesion or during postnatal development in rats6. However, the ependymal region of the adult 
human spinal cord is strikingly different from that of rodents and other primates: although it contains 
ependymal cells, lacks a patent central canal and shows perivascular pseudorosettes7–9. This means that 
observations made in rodents should be validated in human tissue to understand the composition and 
the regenerative potential of this niche. Here we have explored the presence of the ECBS and searched 
for an equivalent of rat and mice CB1HIGH cells in adult human spinal cord.
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Results and Discussion
We found that human ependymal region consistently expresses CB1 cannabinoid receptor (CNR1 gene; 
Table  1). CB1 receptor could be the target of locally produced 2-AG, since we also found expression 
(although non enrichment) of enzymes related with 2-AG synthesis and degradation: diacylglycerol 
lipase α (DAGLA), diacylglycerol lipase β (DAGLB), monoacylglycerol lipase (MGLL) and abhy-
drolase domain-containing proteins – 6 (ABHD6) and –12 (ABHD12). On the contrary, we could 
not find consistent expression of enzymes related with direct anandamide synthesis or degradation 
(NAPE-phospholipase D and fatty acid amide hydrolase, respectively). However, it should be noted that 
alternative enzymatic routes have been described for AEA, involving glycerophosphodiester phosphodi-
esterase and N-acylethalnolamine-hydrolyzing acid amidase that have been not tested here2. We also did 
not find expression of CB2 cannabinoid receptor or the related GPR55 receptor. In previous works, we 
observed expression (but not enrichment) of PPAR-α , another cannabinoid-related receptor1, in human 
ependymal region9.
When compared with ventral horn, only CNR1 (CB1 receptor) was significantly enriched at the 
ependymal region (Table 1). Accordingly, we found a strong CB1 immunoreactivity in central gray matter 
by immunohistochemistry (Fig. 1B–J). But CB1 enrichment in adult humans ependyma is not equivalent 
to that found in rodents: In humans, CB1 is expressed by astrocytes, forming part of the gliosis that 
accompanies central canal closure (Fig.  1C–E) and in the GFAP+ hypocellular ribbon of perivascular 
pseudorosettes (Fig. 1F–K)9,10. CB1 receptor is also expressed in astrocytes from other spinal cord areas 
(Fig. 2), and its intensity is apparently related to high GFAP expression. Accordingly, a strong CB1 expres-
sion has been reported in reactive astrocytes of human pathologies like spinocerebellar ataxia11 or tem-
poral lobe epilepsia12. The role of astrocytic CB1 could be multiple: protection13, metabolism increase14, 
control of inflammation15–17, inhibition of glutamate transporters18 or release of neurotransmitters such 
as glutamate19, ATP and D-serine20.
Interestingly, we obtained some sections from adult individuals in which parts of the central canal 
were patent. In those sections, we found ependymal cells with high expression of CB1 receptors lining the 
canal (Fig. 1L–N), resembling those CB1HIGH cells described for rats and mice6. These cells were mostly 
GFAP-, except for a very dim expression at the apical pole (Fig. 1N), in contrast with strongly GFAP+ 
cells embeded in the ependymal layer (Fig. 1M).
Our results support the existence of ependymal CB1HIGH cells across species, and may encourage fur-
ther studies on this subpopulation, although only in cases when there is central canal patency, i.e. child-
hood and upper cervical levels8,9. But in the majority of adult ependyma, CB1 is enriched in astrocyte 
domains, and cannabinoids may play a different role, that still might be relevant, in terms of homeostasis 
maintenance and response to injury.
Methods
Human tissue was obtained from the HUFA BioBank (Alcorcon, Spain) and the HUB-ICO-IDIBELL 
BioBank (Hospitalet de Llobregat, Spain). Samples were obtained from donor individuals deceased with-
out clinical or histopathological involvement of the spinal cord (Table  2). Donation always included a 
written informed consent from donors while alive or from their families after death. Data from donors 
and handling of samples were carried out after approval by the Clinical Research Ethical Committee 
(CEIC) in Toledo (Spain), in accordance with the Spanish law and International Guidelines (LOPD 




ΔCt Ventral Horn 
vs18S (average) RQ vs Ventral Horn p
CNR1 Hs01038522_s1 8,379754298 13,57232086 57,27 0,012*
CNR2 Hs00361490_m1 – – ND# –
GPR55 Hs00271662_s1 17,13233 18,721182 NCD# –
DAGLA Hs00391374_ml 11,7639845 13,04953063 2,34 0,8
DAGLB Hs00373700_ml 11,1895161 8,199532 14,6 0,51
MGLL Hs00200752_ml 10,5709992 9,519471 0,25 0,44
ABHD6 Hs00977889_m1 12,6129394 14,365685 1,48 0,75
ABHD12 Hs01018047_m1 12,6756672 12,6676875 4,7 0,095
NAPEPLD Hs00419593_m1 13,0519701 6,908164 NCD# –
FAAH Hs01038660_m1 20,2593 19,962125 NCD# –
Table 1.  Relative expression of endocannabinoid system related genes in the adult human ependymal 
region compared with ventral horn. *Significantly enriched in Ependymal region vs Ventral Horn (Student 
T-test). #ND: Non detected in the Ependymal region of any individual; NCD: Non consistently detected 
(detected in less than 3 of the 4 individuals).
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Figure 1. CB1 cannabinoid receptor in adult human spinal cord. (A) Myelin staining of a representative 
thoracic spinal cord section. Square depicts the area shown in (C–E). (B) In low magnification a strong 
CB1 immunoreactivity can be found in dorsal horn, lamina X and ventral gray matter. (C–E) Higher 
magnification of central gray shows CB1 expression in GFAP+ areas surrounding the Vimentin+ cells 
at the ependymary region (EpR). Square highlights the location of a perivascular pseudorosette (PvPR). 
(F–J) Strong CB1 immunoreactivity is found at the GFAP+ domains around and inside perivascular 
pseudorosettes, including the GFAP ribbon at the hypocellular region of the pseudorosette (hcr, outlined 
in white). In PvPRs cells are arranged around a central vessel ((I) arrow). (K) Quantification supports 
qualitative observations: CB1 immunoreactivity is significantly accumulated in GFAP+ areas. (L) Detail 
of the dorsal aspect of an ependymal region with a patent central canal. Square depicts location of images 
M and N. (M) CB1HIGH ependymal cells (empty arrows) can be found intermingled with ependymocytes 
lining the central canal. GFAP+ cells contacting central canal lumen (arrowhead) are CB1−. (N) Detail of 
M, showing a CB1HIGH cell with a dim staining of GFAP in the apical region . ***T student, p < 0.001; CC, 
Central Canal; EpR, ependymal region; hcr, hypocellular region; PvPR, perivascular pseudorosette; WM, white 
matter. Scale bars: A,B = 1 mm; C-E: 100 μm; F-L = 50 μm; M,N = 25 μm.
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Gene expression in human ependymal region. All procedures were performed according to our 
published protocol9. Briefly, fresh frozen spinal cord blocks were cut in 25 μ m thick sections and the 
ependymal region microdissected with a Laser Dissection Microscope. RNA extraction, amplification 
and reverse transcription were performed as previously described9. We also collected microdissected por-
tions of ventral horn, which we used as a non-neurogenic, non-ependymal reference for gene expression.
Gene expression was studied with Taqman PCR Assays (Life Technologies, Madrid, Spain) either 
incorporated in Taqman Low Density Arrays (DAGLA, #Hs00391374_m1; DAGLB, #Hs00373700_m1; 
MGLL, #Hs00200752_m1; NAPEPLD, #Hs00419593_m1) or in individual assays (ABHD6, 
#Hs00977889_m1; ABHD12, #Hs01018047_m1; CNR1, #Hs01038522_s1; CNR2, #Hs00361490_m1; 
Figure 2. CB1 immunoreactivity can be found in astrocytes of other regions in the spinal cord. (A–F) CB1 
is expressed in the processes of GFAP+ and Vim+ astrocytes (arrows) at the dorsolateral white matter. (G–I) 
A strong CB1 expression can be found in astrocytic processes at the subpial region. Scale bars: 25 μm.
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FAAH, #Hs01038660_m1; GPR55, #Hs00271662_s1). We used 18S gene as an endogenous control (18S, 
#Hs03003631_g1). For assays incorporated on TLDAs, we added 1.25 ng cDNA/well. For assays per-
formed individually, we added 1.5 ng cDNA/well. Assays were run on an Applied Biosystems® 7900HT 
Fast Real-Time PCR System. Data were analysed as described9 using automatic detection of Ct, normal-
ized with the endogenous gene (Δ Ct vs 18S). Only genes expressed in at least three out of four samples 
were considered as consistently expressed and included in statistics. Enrichment was defined as higher 
and statistically significant expression in ependymal region vs ventral horn (Student’s t-test with Δ Cts, 
p < 0.05). To obtain folds of enrichment, we used Relative quantity formula, RQ = 2^− Δ Δ Ct.
Immunohistochemistry. To improve signal to noise ratio and avoid autofluorescence, we ampli-
fied CB1 immunoreactivity using Tyramide Signal Amplification System (TSA Plus Cyanine 3 System 
#NEL744001KT, Perkin Elmer, USA). Free floating vibratome sections (40 μ m) were rinsed on 0.1 M 
phosphate-buffered saline containing 0.5% bovine serum albumin + 0.3% Triton X-100. Endogenous 
peroxidase inhibition and antigen demasking were performed as described9. Sections were then blocked 
with TSA Blocking Solution (45′) and incubated for 2 days with primary antibodies diluted in rinse solu-
tion + 10% Normal Donkey Serum: guinea pig anti-CB1 (1:2000, #CB1-GP-Af530-1, FSI, Japan), rabbit 
anti-GFAP (1:2000, #Z0334, DAKO, Spain) and mouse anti-Vimentin (1:300, #M0725, DAKO, Spain). 
Immunoreactivity was visualized by incubating sections with Alexa 488-, Alexa 555- and Alexa 633- sec-
ondary antibodies (1:1000, Invitrogen, Spain) or horseradish peroxidase donkey anti-guinea pig antibody 
(1:300, Jackson Immunoresearch, UK) followed by Tyramide-Cy3 diluted in TSA Amplification Buffer 
(1:50). Samples were analyzed with a LEICA SP5 confocal microscope. We ruled out the interference of 
nonspecific staining by omitting primary antibodies. We set the confocal parameters at a point where no 
signal was observed in these primary antibody controls and those settings were used for all the image 
acquisitions (Supplementary Figure 1A–F). Furthermore, as discussed in several reports, there is a variety 
of antibodies against CB1 receptor, and some of them may show non-specific staining21–23. The specificity 
of CB1 antibody used for this report has been extensively validated by other laboratories and ourselves 
in previous works6,24,25. We show here an additional validation in the Supplementary Figure 1 by using 
immunohistochemistry and TSA amplification on wild type (C57BL/6N) and CB1 knockout mice tissue 
(kindly donated by Dr. Galve-Roperh26). Using restrictive confocal parameters (as we did for humans), 
we got rid out of autofluorescence, background staining and most of the non-specific staining observed 
in the knockout mice that, in these conditions, is limited to a dim intracellular neuronal staining, largely 
different from that observed in the wild type mice (Supplementary Figure 1L-Q). All post-capture image 
modifications were identically performed for controls, including cropping, noise reduction and minor 
adjustments to optimize contrast and brightness.
To quantitatively support CB1 enrichment in the astrocytic area, we calculated the fraction of CB1 
found in GFAP+ vs GFAP− areas on confocal planes (image size 190 μ m × 190 μ m) using Fiji (http://
pacific.mpi-cbg.de). For this, we outlined GFAP borders using manual Threshold with Otsu Filter and 
used this ROI on the CB1 image corresponding to the same confocal plane. We measured CB1+ Area 
inside and outside the selection (GFAP+ and GFAP− areas, respectively) and expressed them as % of total 
CB1 staining (Fig. 1K). We used Student T-test for statistical comparisons.
Autopsy number Cause of Death Gender Age Coded as Postmortem delay Used for
BC01015 Unknown. No significant neuropathological alterations in the spinal cord Male 60 Control Unknown IHC
BC01684 Acute Hypoxia-ischemia Male 27 Control Unknown IHC
A07/00044 Cardiopulmonary arrest Male 39 Control 3 h 30 min IHC
A07/00067 Refractary septic shock and cardiac arrest. Ischemic cardiopathy Male 47 Control 4 h 55 min IHC
A10/00017 Hepatic metastasis. Probable pancreatic neoplasia Male 52 Control 03 h IHC
A07/00041 Multiorganic failure. Gastric tumour Male 43 Control 5 h 55 min IHC, LCMD
A07/00084 Refractary septic shock Male 46 Control 15 h IHC, LCMD
A10/00026 Multiorganic failure. Severe broncopathy Male 61 Control 3 h 55 min LCMD
A05/00134 Carcinoma and metastasis. With brain but not spinal cord metastasis. Female 32 Control 11 h 45 m LCMD
A11/00052 Endocarditis. No neuropathological features Male 76 Control 06 h 30 m LCMD
A12/00046 Cardiac arrest. No neuropathological features Female 75 Control 06 h10 m LCMD
Table 2.  Postmortem Spinal Cord tissue samples used for immunohistochemistry (IHC) and/or Laser 
Capture Microdissection (LCMD).
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